Gx Acquisition Corp II (CELUW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Gx Acquisition Corp II Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 11,713 | $410.98 | $117.13 | -$293.85 | -71.5% |
Gx Acquisition Corp II (CELUW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gx Acquisition Corp II ever had a stock split?
Gx Acquisition Corp II Profile
| Biotechnology Industry | Healthcare Sector | Robert Joseph Hariri CEO | NASDAQ (CM) Exchange | 151190113 CUSIP |
| US Country | 120 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Celularity Inc. stands as a pioneering entity in the biotechnology arena, focusing primarily on the development of innovative cell therapies. Based in Florham Park, New Jersey, and established in 1998, Celularity embarked on a mission to harness the potential of placental-derived allogeneic cell therapies. The company targets a wide range of diseases including cancer, immune disorders, and infectious diseases, operating through three strategic segments: Cell Therapy, Degenerative Disease, and BioBanking. It has carved a niche for itself by propelling forward with leading therapeutic programs such as CYCART-19 for lymphoma treatments and CYNK-001 for acute myeloid leukemia, among others. By engaging in key partnerships with other biotech firms like Sorrento Therapeutics and Regeneron Pharmaceuticals, Celularity enhances its competitive edge in biotechnology and continues to advance the realm of cell therapies.
Products and Services
CYCART-19: An allogeneic CAR-T cell therapy targeting non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL), showcasing the advancement of Celularity in addressing hematologic cancers.
CYNK-001: A groundbreaking allogeneic unmodified natural killer cell therapy undergoing Phase I/II clinical trials for acute myeloid leukemia (AML). This initiative underscores the company's dedication to leveraging natural killer cells in combating cancer.
APPL-001: A genetically modified cell therapy derived from placental cells aimed at treating Crohn's disease, evidencing the company's commitment to tackling autoimmune and degenerative diseases.
Additional Therapies: The development pipeline includes CYCART-201 for NHL, MCL, and HER2 positive cancers; CYNK-301 for relapsed or refractory AML; CYNK-302 targeting non-small cell lung cancer; and pExo-001 for osteoarthritis. These projects highlight the broad spectrum of Celularity’s therapeutic pursuits.
Surgical and Wound Care Products: Celularity extends its market presence to surgical and wound care through products like Biovance, Biovance 3L, Interfyl, and Centaflex, offering innovative solutions beyond cell therapy.
BioBanking: Under the LifebankUSA brand, Celularity provides biobanking services, preserving stem cells from umbilical cords and placentas. This service underpins the company's foundation in harnessing and preserving the life-giving potential of birth-related materials for future therapeutic needs.
